Kanghong Pharmaceutical receives approval for KH607 clinical trial
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SZSE:002773) announced it has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The approval is for KH607 tablets, a Class 1 innovative chemical drug, indicated for the treatment of postpartum depression. KH607 is a small molecule γ-aminobutyric acid A (GABAA) receptor positive allosteric modulator developed independently by the company, in the form of oral solid preparation tablets. The company had already received approval in 2023 to conduct clinical trials for treating depression. Previous research results have indicated that KH607 tablets are safe and effective, potentially filling a gap in the domestic postpartum depression treatment field, which currently lacks specific therapeutic drugs. The company cautions that the research, clinical trial, review, and approval processes for drugs are subject to significant uncertainties, and investors should exercise caution and be aware of investment risks.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Chengdu Kanghong Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime